• HempFusion Wellness Inc. has announced the launch of certain Probulin Probiotics products in China to be sold on Alibaba Group Holding’s Tmall Global
• Tmall offers a number of features and advantages, which will be pivotal in helping HempFusion earn significant revenue
• Probulin Probiotics is recognized as one of the fastest-growing probiotics brands in the United State Natural Products Industry, according to SPINS syndicated data, and by entering the Chinese market, HempFusion hopes to replicate this growth in the vast Chinese marketplace

The Chinese probiotics market is booming and is expected to reach $12.75 billion in 2022, up from $6.47 billion in 2017 (https://ibn.fm/FCQdc). Moreover, with more and more people in China appreciating the health benefits associated with the use of probiotics, according to a 2020 survey (https://ibn.fm/cg0TQ), the conditions seem favorable for HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 800) through its wholly-owned subsidiary, Probulin Probiotics, LLC, to thrive. In a recent news release, HempFusion, a leader in the health a wellness cannabidiol (“CBD”) industry, announced that it would target this Chinese market through Probulin (https://ibn.fm/pfsfT). Probulin will offer certain products on Alibaba Group Holding’s Tmall Global, with shipments expected to commence in late March. Thereafter, HempFusion’s Probulin products will be available for purchase – the go-live date is currently set at March 29. The choice of this date is strategic for HempFusion as it will ensure that the Probulin products are purchasable before the mid-year 618 shopping festival, one of China’s largest single-day shopping extravaganzas, which is usually held in June. In 2020, it shattered records with over $98.52 billion in sales in 24 hours. By tapping into the massive Chinese market, HempFusion anticipates a significant revenue increase. “This strategic launch provides us with a tremendous opportunity to reach one of the largest online consumer bases in the world and drive significant revenue for the company,” said Jon Visser, HempFusion’s Chief Revenue Officer. This is thanks, in part, to the features and benefits offered by Tmall Global. Tmall Global is the world’s largest cross border online marketplace that enables foreign-based vendors to access the Chinese market, reaching more than 750 million potential consumers in mainland China, Hong Kong, Macau and Taiwan. The platform provides a win-win situation for both the sellers and consumers as the Chinese consumers, whom the vendors target, have a high affinity for imported products, which they consider as being high-quality. Tmall also leverages Alibaba’s elaborate consumer analytics tools to provide the sellers with insights into Chinese consumers’ shopping behavior (https://ibn.fm/Klibc). While these features and benefits are some of the reasons why HempFusion may have chosen Tmall, perhaps the most significant – because of its potential to influence sales and revenue – is that the platform regularly engages consumers with brands through live streaming, educational videos and group chats. HempFusion and Probulin could take full advantage of this, given that most Chinese consumers lack product understanding of probiotics despite acknowledging their health benefits. “Although China’s probiotics market is booming, consumers are not well-equipped in terms of scientific knowledge,” reads an article summarizing the findings of a report on the probiotics market in China. “One of the major knowledge gaps is not knowing the differences between probiotics, prebiotics and lactic acid bacteria.” With the interactive tools on Tmall, it would be befitting for Probulin to use the platform to bridge the knowledge gap. By creating awareness, HempFusion would surely appeal to more buyers, translating to additional revenue. “Probulin looks forward to utilizing our growing team of celebrity influencers to take advantage of these innovative, interactive opportunities to reach new consumers in a fun and entertaining way,” Visser continued. On his part, Dr Jason Mitchell, N.D., HempFusion’s co-founder and CEO, hailed the launch as a tremendous milestone that would also be an opportunity to educate the Chinese market on the many health benefits of probiotics. “We believe Probulin to be the first American company to deliver cold and protected probiotic supplements direct to Chinese consumers,” Dr Mitchell stated. “In addition, our scientifically validated MAKTrek® 3-D Probiotic Delivery System is designed to protect and nourish the probiotics so that more can arrive alive in the gut. These two distinguishing factors result in a positive influence on the microbiome and overall wellness.” HempFusion’s Probulin is recognized as one of the fastest-growing probiotics brands in the United States Natural Products Industry according to SPINS syndicated data. With its strategic entry into the Chinese market and the favorable conditions therein, the company may replicate this growth in the new territory. HempFusion also recently announced that its OTC Topical Products were ranked number one in both sales dollars and units sold at a major Food & Drug Mass (“FDM”) retailer according to a recent NielsenIQ share report (https://ibn.fm/bScHY). For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• COVID-19 patients can suffer from bevy of ailments from fatigue to cardiac conditions long after virus has left their body
• Follow-up monitoring is not convenient or cost effective
• Mediscan, subsidiary of Healthtech Solutions, has brought to market a solution that has potential to become standard of care, including helping emerging “long hauler” crisis
• Mediscan’s technology converts two-dimensional ultrasound images into 3D, high-definition format in under one minute for immediate attention at point of care

Call them “long haulers” or people with “long COVID” or any other number of names, but don’t call anyone “recovered” even though coronavirus free. There is a growing chorus of patient voices and published studies suggesting at least half (and potentially up to 80%) of COVID-19 patients continue to exhibit troublesome symptoms that affect their quality of life long after tests show no viral load present (https://ibn.fm/JevnA). While all too often dismissed by physicians, awareness of the chronic symptoms has earned the attention of the National Institutes of Health, which has proposed “post-acute sequelae of SARS-CoV-2 infection (‘PASC’)” as an all-encompassing name for the malady. Symptoms can range from chronic fatigue to cardiac conditions, highlighting the need for widespread adoption of simple and fast standards of care to monitor organs and tissue to best understand a patient’s condition. That’s exactly what upstart Mediscan Inc., a subsidiary of Healthtech Solutions (OTC: HLTT), is bringing to the table with its innovative software application that converts two-dimensional ultrasound images into a 3D, high-definition format in under one minute for immediate attention at the point of care. Mediscan is bridging a big gap in healthcare today where access to magnetic resonance imaging (“MRI”) and computed tomography (CT or CAT) machines often aren’t readily available, much less convenient for immediate care. The poignant fact is that many of those facilities try to avoid even having COVID-positive patients on site—that goes without mentioning the high costs for those tests. An MRI in the U.S. in 2019 averaged $2,611, according to GE Healthcare citing Time Magazine (https://ibn.fm/JDkNE). CT scans can cost up to $3,275 (www.NewChoiceHealth.com). Mediscan is looking to disrupt the $134 billion U.S. medical imaging market (https://ibn.fm/XaPCv) with its cloud-based software that reconstructs an ultrasound’s analog 2D grayscale image into digital 3D HD format nearly instantly. For the first time, medical professionals will have at their fingertips images containing data-driven metrics that previously were only available through X-rays or MRI and CT scans. A video discussing the technology is available for viewing online (https://ibn.fm/cpumJ). Applications abound for the user-friendly technology, including a physician’s office, sporting facilities and events, isolation wards, emergency rooms and on-location for emergency medical services (“EMS”) personnel, to name a few. Anywhere an internet signal can be used – which is nearly everywhere anymore thanks to hot spots – once certified, the Mediscan technology will be able to provide almost immediate, actionable information on heart, lungs, tendons, skin and other organs. Furthermore, the Mediscan app integrates with all the popular electronic medical record (“EMR”) systems for comprehensive record keeping. An opportunity is present for market penetration by utilizing the technology for PASC with any of the nearly 30 million Americans diagnosed with COVID-19 for an easy point-of-care diagnostic that is reliable and repeatable to track progression or regression without the inconvenience and high cost of legacy technologies. Once in the doctor’s office and other locations, it’s hard to imagine Mediscan not becoming an integral part of patient care, where a doctor or nurse could say, “Let’s take a closer look” and have data in a matter of minutes using only a portable ultrasound device and the Mediscan app. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• PACR recently closed share purchase agreement to acquire Lords of Grasstown Holdings Ltd.
• Lords of Grasstown is iconic brand with loyal following anchored in motorcycle culture of Pacific Northwest
• PACR closed non-brokered private placement with aggregate gross proceeds of $1,340,685.90

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, recently announced the closing of a share purchase agreement with the shareholders of Lords of Grasstown Holdings Ltd. whereby the company will acquire all its issued and outstanding shares. The company also announced the closing of its previously announced non-brokered private placement with aggregate gross proceeds of $1,340,685.90 to be used for business and brand development, and as general working capital. Grasstown is a well-established brand that fuses motorcycle and cannabis culture. Spawned from the vision of Tyler Hazelwood, the founder and director of the iconic Lords of Gastown brand, Grasstown has built a loyal following anchored in the motorcycle culture of the Pacific Northwest. The total purchase price pursuant to the share purchase agreement will be comprised of a cash payment of $50,000 that will be payable within 30 days of the closing date along with the issuance of 6,000,000 common shares of the company within five business days of the transaction closing date. “This acquisition marks a major milestone for the company with a move into the U.S. Cannabis Market, predominantly in California, with the Grasstown Brand,” said Pac Roots CEO Patrick Elliott (https://ibn.fm/noGUJ). “The team at Lords of Grasstown have done a remarkable job branding, designing, launching and marketing Grasstown in B.C. and California. “The alliances are real and the followers like what they see,” he said. We are thrilled to develop and expand Grasstown from Prince Rupert to San Diego. Tom and Tyler are authentic artists with a strong pedigree to prove it. We are inspired to have them as part of the team.” PACR also announced the closing of its non-brokered private placement that raised $1,340,685.90 in aggregate gross proceeds through the issuance of 7,448,255 units, each consisting of one common share and one purchase warrant with the latter exercisable at $0.30 per share until February 23, 2024 (https://ibn.fm/sPg56). Registrants were paid finder’s fees of $75,294.51 in cash along with 408,303 finder’s warrants that are exercisable into one common share at $0.18 per share until February 23, 2024. All private placement securities are subjected to a four-month hold period that expires on June 24, 2021. Pac Roots Cannabis Corp. is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach. The company focuses on elite cannabis genetic development for maximum yields, high profit margins, and superior quality strains that meet the high standards of the growing cannabis market. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• TAAT launched on the ground in December 2020; by the end of January, 60% of retail locations had sold out and were reordering
• Company’s e-commerce site experienced similar success, with C$100,000 in sales in first five days of operation
• TAAT executive team key to game-changing product’s meteoric rise

A company is only as strong as its leaders, and TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) has assembled an executive team whose expertise and insight has already been proven by the company’s impressive showing in just the first few weeks of its product launch. TAAT(TM) is a life sciences company committed to providing legal-aged smokers with the smoking experience they enjoy but without the nicotine and tobacco. In December 2020, TAAT(TM) launched its flagship product — TAAT(TM), a tobacco-free, nicotine-free cigarette (https://ibn.fm/YAHUC). Through a distribution agreement with CROSSMARK (https://ibn.fm/KI2lI), a sales and merchandising agency for CPG products with an expertise in the tobacco alternative space, the new product rollout began in Ohio. Initially TAAT(TM) was available in both chain and independent tobacco retail locations across the state. By the end of January, 60% of tobacco retailers that had carried TAAT for three or more weeks had placed reorders for the game-changing product. That success on the ground was replicated online when the company launched its e-commerce portal on Feb. 17, 2021. In addition to typical cartons of the cigarettes, the site offered a Taste Explorer Bundle consisting of one 20-stick pack of each of the three TAAT varieties: Original, Smooth and Menthol. TAAT reported an incredible C$50,000 of sales within the first 48 hours of operation, and by the end of the first weekend, sales had topped C$100,000 (https://ibn.fm/gAYxW). The swift rise of TAAT is certainly a testament to the company’s disruptive product, but the role of its executive team cannot be overlooked. The strategic research, development, planning and launch of the product was carefully crafted by a team of professionals with extensive experience and invaluable insight into what it takes to revolutionize an industry. Setti Coscarella brings a wealth of knowledge across a variety of disciplines to his role of TAAT CEO. Building upon experience in investment banking, private equity and entrepreneurship, Setti served as lead strategist at Philip Morris International over its Reduced-Risk Products (“RRPs”) division beginning in 2017. In that position, Coscarella gained a unique perspective on positioning smoking alternatives and developing programs that could help smokers discover and successfully convert to RRPs. That insight drives TAAT in its current trajectory to transform the smoking experience. Chief revenue officer Tim Corkum also hails from PMI, where he spent more than two decades in a variety of roles where he led international commercialization initiatives for combustible cigarettes and new products in the RRP category. He has held senior positions in business development, sales strategy, corporate affairs and key account management. TAAT founder Joe Deighan has been involved in smoking alternatives since 2012, when he founded vape liquid maker JJuice. The company was available in all 50 states and in 26 other countries, in addition to private label production for other brands. Deighan sold the company in 2017 but brings his expertise and insight into his role overseeing R&D and production. Savvy leadership plus innovative products make an almost unstoppable combination, and TAAT is certainly exemplifying that as it is creating an irresistible new smoking product that offers all the pleasure with none of the tobacco or nicotine risk. For more information, visit the company’s website at www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s License
• Award of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business sales
• Pure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out under auspices of Toronto Institute of Pharmaceutical Technology
• Functional mushroom, psychedelic drug market is forecast to grow to value of $6.85 billion by 2027

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, announced that its wholly owned subsidiary, Pure Mushrooms Corp., had submitted an application to Health Canada for a Dealer’s License under the Controlled Drugs and Substances Act (“CDSA”) (https://ibn.fm/W0X2t). Under the CDSA’s regulations, companies are required to obtain a license issued by Health Canada to carry out a variety of regulated activities with controlled substances. Among other items, the award of a license would effectively enable Pure Mushrooms Corp. to:

• Procure controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
• Research and manufacture of controlled substances such as psilocybin and psilocin
• Business-to-business sale of controlled substances, including by export
• Sell controlled substances via pharmacies

Prior to Pure Mushrooms Corp.’s license application, Pure Extracts had revealed that it had already commenced a study into the formulation and manufacturing of psilocybin-based active treatments, with oral tablets, capsules and nasal gels set to be used as investigational products. The study, which was set to focus on the formulation, manufacturing and clinical bioavailability testing of rapid onset psilocybin forms, was being carried out ahead of the company’s Dealer’s License application and, as such, was to be carried out at the Toronto Institute of Pharmaceutical Technology (“TIPT”) under the auspices of Dr Alexander MacGregor, a key scientific advisor to the company (https://ibn.fm/X7n3K). Pure Extracts has actively sought to diversify its existing toll processing and extraction businesses through a new business vertical into the functional mushrooms sector. To that end, the company recently announced that it had begun work on a fourth unit within its 10,000 square foot, British-Columbia based, purpose-built facility, destined towards facilitating its research and development into psilocybin and functional mushrooms as a whole (https://ibn.fm/JcsJV). Gaining a Dealer’s License from Health Canada would allow Pure Mushrooms Corp., the ability to carry out extraction research and development into psychedelic compounds such as psilocybin and psilocin. This in turn would prepare the company to work with partners such as medical doctors, pharmaceutical companies and pharmacies in an eventual future in which clinical trials could lead to the advancement of micro-dosing and the legalization of psychedelics. Pure Extracts CEO Ben Nikolaevsky stated in reference to the company’s Dealer’s License application, “We are grateful to have the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries in assisting that we submitted a fully compliant Dealer’s Licence application to Health Canada. As a plant-based extractor bringing functional mushroom products to market in Q2, we are very excited to be laying the groundwork for our move into the controlled substances world of psychedelic extracts.” For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• New York City ramps up rapid testing efforts, opens 11 rapid-testing sites; others to follow
• Mayor notes that low-cost, rapid-testing made available to public is key to accelerating economy’s re-opening
• UME offers rapid -testing kits, provides products and services essential for curbing pandemic and jumpstarting economic recovery

United Medical Equipment Business Solutions Network (“UME”), a trusted supplier of COVID-19 antigen and antibody testing kits, is offering a key product that could impede the spread of the virus and speed up economic recovery. A top U.S. testing official announced a scale-up in the country’s diagnostic efforts, touting both health and economic benefits of rapid testing outside the lab. New York City is wasting no time to leverage the power of this low-cost, high-impact option as the city has announced the launch of its Forward Rapid-Test Program (https://ibn.fm/RmtcD).

The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The city has initially announced that 11 sites will open with the capacity to conduct more than 5,000 tests every day. Additional locations are planned across the city and other parts of the state in the coming weeks.

State officials have noted that testing will be a key part of New York’s post-pandemic recovery because it will help the state accelerate the re-opening of its economy. Testing sites have been situated throughout the city to encourage and support economic activity while minimizing risks to people’s health.

The widespread rapid testing is being rolled out in other countries too. The UK government is also looking at introducing rapid lateral-flow testing to open the parts of the economy that could not open last year, including night clubs and theaters. “That [rapid testing], in combination with vaccination, will probably be the route forward,” said UK Prime Minister Boris Johnson (https://ibn.fm/r5rYk).

As a company committed to providing essential products and services during the pandemic, UME is a trusted supplier of FDA-approved COVID-19 rapid test kits (https://ibn.fm/48e2i). The rapid test is designed to detect coronavirus antibodies in the bloodstream of infected individuals within 10 minutes, which helps position the company at the core of the strategy to bring both economy and society back to normal. The test can also help identify whether a person has protection against the coronavirus.

Finally, UME also offers a unique mobile solution that involves on-call onsite COVID-19 Rapid Testing Mobile units. These units involve mobile testing specialists and experienced medical staff members who provide onsite COVID-19 rapid testing. Capable of nationwide deployment for extended periods, they are especially beneficial for securing employee safety. With an offering deemed essential during the pandemic, UME is well-positioned as an all-around provider of highly-sought-after products and services that may prove crucial for getting the society and economy back to normal.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Asia Broadband Inc. recently signed a letter of intent (“LOI”) to acquire a 200-hectare property housing two gold mining sites, a processing facility and existing infrastructure
• The property, estimated to be worth about $30 million, is part of the bigger picture as the company is expected to launch a 100% gold-backed token soon to diversify its revenue generation streams
• The company outlined its AABB Gold Token’s characteristics in a recent news release

Asia Broadband (OTC: AABB), a resource company focused on the production, supply, and sale of precious and base metals, primarily to Asian markets, has made strides on several fronts since its February 2021 development update on the soon-to-be-launched AABB Wallet and AABB Gold token. According to recent news releases, AABB signed a letter of intent (“LOI”) to purchase an historic production gold mine property and on-site processing facilities in the prolific mining region of Mascota in Jalisco, Mexico, and also clarified the exact characteristics of the AABB Gold token (“AABBG”). The signed LOI sets the wheels in motion for the eventual acquisition of the 200-hectare property, located about 3 kilometers from Barra de Navidad – a small town on the western coastline of Mexico’s Jalisco state – subject to further due diligence and negotiations. The property houses two mine sites, a processing facility capable of processing 50 tons of gold per day and other existing infrastructure (https://ibn.fm/p1vuz). In total, Asia Broadband is expected to pay about $30 million for the property, an investment that will bring the company closer to fulfilling its strategic vision and goal. Fundamentally, AABB aims to differentiate itself from its competitors as well as increase shareholder value by launching a gold-backed digital currency, wallet and exchange. It will back its gold token with physical gold acquired from future mining production, such as mining sites at the 200-hectare property, and gold purchased from cash reserves or credit. So, the purchase is part of a bigger picture. Per its February development update, AABB’s wallet and token developer Core Holdings Corp (“CSHC”) was at an advanced stage of testing the wallet applications on both iOS and Android, in addition to continuing the enhancement of AABB’s gold token website. The developer had also begun the creation of AABB’s cryptocurrency exchange (https://ibn.fm/JEAzu). With the information on the progress of the development of AABB’s wallet and exchange already in the public domain, Asia Broadband sought to provide a similar level of clarity regarding its gold token. In the March 9 news release (https://ibn.fm/xAeza), AABB pointed out that its cryptocurrency token will have the following characteristics:

• AABBG will be backed 100% by physical gold held by AABB
• At present, AABB holds $30 million in physical gold
• AABB will release approximately 5.5 million tokens in the initial token release
• The price of each token will be equivalent to the current price of one-tenth (0.1) gram of gold plus a 2% transaction fee
• The price of each token will be tied to and supported by AABB at the market price of gold at a minimum
• The minimum supported price of AABBG will increase or decrease according to the fluctuation in the price of gold
• The price of AABBG will also be driven by market demand
• Purchase of AABBG will be through AABB Wallet
• Buyers will need to hold existing cryptocurrencies to purchase AABBG
• Purchase of AABBG will be finalized upon depositing existing cryptocurrencies from third-party wallets into AABB wallet in exchange for AABBG
• AABB Wallet will allow the intra-wallet transfer of AABBG between purchasers and people with AABB Wallet
• AABBG tokens will not be exchangeable within the AABB Wallet for other cryptocurrencies

Being a source of shareholder value, the AABB Gold token is a strategic offering aimed at diversifying the company’s revenue. AABB will rely on two revenue-generating streams: transaction fees and the token’s market-demand-driven price appreciation. The company anticipates that an increase in the token circulation will boost the revenue earned from transaction fees, its primary stream. At the same time, AABB is banking on the limited release of the tokens as well as the expanded use and velocity of token exchanges as the main drivers of growth for its secondary stream. Notably, gold-backed tokens are attractive investment options because they offer more stability than other digital currencies (https://ibn.fm/vLrqP), suggesting that Ethereum-based AABBG is bound to appeal to cryptocurrency enthusiast upon launch. Asia Broadband’s objective is for AABBG to become a worldwide standard of exchange that is secured and trusted with gold backing. With the recent announcement regarding the LOI, AABB’s strategic approach and AABBG’s attractiveness as a gold-backed token due to its inherent stability, the conditions seem favorable for the company to actualize this goal. For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025
• Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal
• STREAMWAY Systems eliminates waste transport, disposal costs, equipment relocation and risk of exposure to potentially contaminated fluids.

For every healthcare facility, particularly hospitals and surgical centers, disposal of waste fluids presents a unique set of challenges related not only to regulations but also staff safety. Improper disposal can result in hefty fines and possibly risk exposure to infectious fluids. For the most part, the legacy technology of draining fluid into a canister is the hospital standard, making the industry ripe for innovation. After a year of the coronavirus pandemic leading to postponements of countless elective surgeries, Skyline Medical, a division of Predictive Oncology (NASDAQ: POAI), looks to have well-timed renewing development of its new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management.

According to analysts at MarketsandMarkets, the fluid management systems and accessories market is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a 13.6% compound annual growth rate (https://ibn.fm/Vo563). The firm cites several growth drivers, including an increasing number of minimally invasive surgeries, more government funds and grants for endosurgical procedures and a rising number of ESRD (end stage renal disease) patients. They also point to technological advancements in fluid management systems, which falls right into Skyline Medical’s wheelhouse.

Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. A video showcasing the system is available at (https://ibn.fm/GZGlG).

The STREAMWAY System is a major step forward compared to the way many hospitals currently deal with waste fluids, which can amount to dozens of liters from a patient during a single operation. Operating under today’s standards, once a waste fluid container is filled, it is wheeled down a hallway to be emptied. This can even mean stopping mid-operation to empty a container.

The wall-mount STREAMWAY System ties into a facility’s existing plumbing system. During a surgery or procedure, a single-use filter is snapped into place, a suction tube connected to the unit and proper vacuum level programmed into the display, and the unit takes it from there, calculating the collected amount of fluid while safely disposing of it through the drain system.

For interventional radiology procedures, such as paracentesis and thoracentesis, the unit can also be programmed to remove a designated amount of fluid. Once complete, the filter is disposed of and a bottled STREAMWAY solution is attached to the unit, cleaning it in less than five minutes. The system is centered on elimination of waste transport, disposal costs, equipment relocation and risk of exposure to potentially contaminated fluids.

The new generation of the system will include:

• A 25% reduction in unit size
• Modularized subassemblies and drop-down cover to streamline assembly and servicing
• Upgraded software providing state-of-the-art on-screen graphics
• New technology for on-screen training as required.
• An automated dripless system for filter changes between procedures
• Reduced electrical and mechanical internal connections increasing vacuum efficiency
• New integrated PC board providing real-time fluid waste management
• Eliminated relays and inputs/outputs

“Skyline Medical plans to follow shortly with a Generation 3 Plus machine, which includes an integrated on board vacuum pump so the facility vacuum supply will not be required or at the very least can be augmented if needed,” commented Predictive Oncology CEO Dr. Carl Schwartz.

Overall, the new design will be smaller, lighter, and easier to install with the goal of improving operator reliability, reducing manufacturing costs, increasing durability and simplifying servicing. From a regulatory standpoint, the changes do not affect the intended use of the system, meaning no separate 501(k) medical device submission is required with the Food and Drug Administration.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Bladder cancer is the fourth most common cancer in men andexpected to cause more than 17,000 deaths in the United States this year
• Imagin Medical is advancing its patented bladder cancer visualization technology toward commercialization and FDA approval, expecting the technology to revolutionize blue light cystoscopy procedures and improve patient outcomes in the process
• Imagin is funding its efforts with $2.165 million raised towards its convertible note offering
• Rollout of the company’s manufacturing process was delayed about nine months as a result of the COVID-19 pandemic.but Imagin and its production partner remain on its revised schedule
• The company expects to expand its product line once the bladder cancer technology rolls out, adapting its IP for use with other contrast dyes so the technology can be used in additional endoscopic procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF) announced on March 16 that its product development partner, ISO 13485:2016-certified manufacturer, Lighthouse Imaging, is making progress towards commercial-stage manufacturing capability of the novel, state-of-the-art bladder i/Blue Imaging System (TM) for use in bladder cancer visualization procedures.

“Prior to Imagin’s selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System (TM) in October 2020, the Company received multiple fully functional feasibility units from its original design partner, Optel, Inc.,” the news release states (https://ibn.fm/34rXB). “Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration and to ensure final device performance, compliance with all applicable regulatory standards, and optimal manufacturability to meet both cost targets and anticipated user demand.”

The i/Blue Imaging System will improve the ability of surgeons to view bladder tumors during cystoscopy procedures. Bladder cancer is the sixth most prevalent cancer in the US and the fourth most common cancer in men and was expected to directly result in more than 17,000 deaths during the past year in the United States, with similar statistics anticipated for 2021 (https://ibn.fm/wcmFw).

The challenge for surgeons is to get a full view of any tumors on the bladder wall so they can be removed in their entirety. The existing technique of using blue light in cystoscopies to view tumors stained with a pink contrast dye makes it possible for them to view all the contours of the tumors and ensure they are completely removed, potentially reducing the rate of recurrence in a cancer renowned for its repeat incidence rate.

Blue light cystoscopy is still an emerging technique, despite its reported rate of success and cost-effectiveness in medical studies (https://ibn.fm/66wE3). Two primary obstacles to wider adoption identified by Imagin include a reluctance by hospitals and clinics to upgrade existing equipment, and the technological imposition of blue light procedures that require surgeons to repeatedly switch back and forth between standard white light camera images and blue light camera images as they visualize the patient’s internal landscape.

Imagin’s patented system responds to both concerns, first by developing a device that can easily be adapted to nearly all existing cystoscopes, eliminating the need to replace surgical tools they already own, and second, by establishing a camera system that delivers white and blue light images side-by-side on a single screen so they can be viewed simultaneously.

The advent of the COVID-19 pandemic set the transition from development to manufacturing back by about nine months, meaning the system will be available for commercial production in 2022. In the meantime, Lighthouse continues laying the groundwork for meeting the FDA’s rigorous standards for surgical devices.

The good news is that Lighthouse’s program has stayed on schedule and we expect it to remain on target going forward,” Imagin CEO and President Jim Hutchens stated.

The project is primarily being funded by a $3 million convertible note Imagin undertook late last year (https://ibn.fm/yKZHJ).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• InsuraGuest Technologies is a leading insurtech (insurance + technology) company that offers its Hospitality Liability coverage to the hotels and vacation rental sectors
• The latest expansion will offer accidental medical protection to hotels and vacation rental customers who also own properties abroad
• The company is looking to enter the European and Canadian markets in 2021, two promising markets, given the size of the SMEs and projections on revenue generated from the traditional hospitality sector and vacation/holiday rental homes
• InsuraGuest already has existing insurance partnerships with leading underwriting companies and distribution with major insurance agencies

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF), a leading insurtech company that is leveraging its proprietary software platform to disrupt the insurance landscape, has expanded its Hospitality Liability coverages to include worldwide accidental medical protection for U.S.-based customers. Through the wholly owned U.S. subsidiary InsuraGuest Hospitality, the company will now provide coverage to U.S. hotel and vacation rental customers that have properties located outside the country (https://ibn.fm/XDue0). This decision is in line with the company’s plans to expand the reach of its insurtech platform and services worldwide, starting with the European and Canadian markets. “It has always been our goal to expand InsuraGuest worldwide so we can capture the 6.8 billion hotel nights stayed and 448.7 million vacation rental users in major worldwide markets,” InsuraGuest Technologies Chairman and CEO Douglas Anderson explained. “Our ability to offer the accidental medical portion of our Hospitality Liability coverage to our U.S. members’ properties worldwide is the first step for us to become the global provider we have envisioned.” A look at the European and Canadian markets shows the motivation behind this expansion drive. A publication by the European Commission shows that small and medium-sized enterprises (“SMEs”) contribute 50% of Europe’s GDP. As at March 2020, there were 25 million SMEs, which employed 2 out of 3 Europeans (https://ibn.fm/7D8mU). The European vacation/holiday rental homes are projected to generate about $23.99 billion in revenue in 2021, with the figure expected to reach $34.18 billion by 2025 (https://ibn.fm/ChzOP). The revenue from Canadian holiday rental homes is forecasted to reach $1.40 billion in 2021 and $1.90 billion by 2025 (https://ibn.fm/0w1P1). These figures exclude the income from the traditional hospitality industry, which is expected to generate $79 billion and $4.89 billion in 2021 in Europe and Canada, respectively. To back this expansion, InsuraGuest already has existing partnerships with underwriters and distribution with major insurance agencies to sell in these new markets. Therefore, they looks well-positioned to enter the new market successfully. InsuraGuest is transforming the way insurance is delivered, and the fact that it is eyeing new markets means that it is looking at the transformation from a global perspective. InsuraGuest Technologies is at the center of a global, technology-driven insurance shakeup. A McKinsey report on the digital disruption in insurance terms the present era as “The age of innovation. Insurers have a choice: be disrupted or be the disruptor with new products, services, and business models.” It further discussed new ways in which technology has disrupted and is disrupting the insurance sector, among them the fact that new underwriting approaches have emerged. One such disruption, which InsuraGuest’s products happen to be a part of, is on-demand insurance. The report continues, “In addition to facilitating the underwriting of small amounts of cover, real-time data can enable the provision of ‘episodic’ or on-demand cover for short periods” (https://ibn.fm/ChS42). This statement perfectly describes two of InsuraGuest. The company’s platform provides digital insurance to multiple sectors, making it well-suited for the current insurance market conditions. Further, the software platform supports multiple property management systems used in the hospitality industry – over 82 PMS systems available in the market – through back-end integration, enabling it to deliver the Hospitality Liability coverage. This coverage, a specialized insurance policy covering property, casualty, accidents, and health claims, is activated when a guest checks in and deactivates once they check out. This insurance policy is also unique because it passes the cost to the guest (https://ibn.fm/S1u6U) and is available for hotels and vacation rental properties. The InsuraGuest solution further helps hospitality operators lower their insurance premiums and risks deriving from third-party liability claims by absorbing the risks itself. The majority of hotel operators file their accident or small property claims through their general liability policies, resulting in higher premiums. The higher the risk, the higher the general liability insurance prices will be. InsuraGuest changes this dynamic by transferring the risk from the hospitality operator by having guests pay a nominal fee per night. InsuraGuest then pays out the coverage for these small claims, potentially keeping the hotel operator’s general liability premiums untouched, resulting in lower expenses for property owners. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI